Gilead will present five-year follow-up data on a lymphoma treatment
Gilead's Kite unit will present long-term data on its lymphoma treatment Yescarta and new data on anito-cel for multiple myeloma at ASH 2026. The iMMagine-1 trial data supports the FDA review of anito-cel, with a PDUFA target date of December 23, 2026. Yescarta's five-year follow-up data will provide long-term evidence for its use in high-risk large B-cell lymphoma.
How this was made
The 30-second read
Why it matters
Long-term follow‑up data are critical for assessing commercial potential and pricing power of Gilead's cell‑therapy franchise.
Market read
First disclosure of extended efficacy data could move Gilead's stock and influence sector sentiment.
What to watch
Regulatory timeline for BLA filing and competitive bispecific antibody landscape may temper price reaction.
Background
Gilead's Kite unit is advancing multiple CAR‑T programs; Yescarta is already approved, while anito‑cel is in pivotal trials.
Ticker impact
Gilead will present five-year follow-up data on Yescarta and 18‑month data on anito‑cel at ASH 2026, providing new clinical trial results.
potential upside if data confirms durability, downside pressure if safety concerns emerge
First disclosure of extended follow‑up results; material for valuation of Gilead's cell‑therapy pipeline.
Market effects
Positive data could boost the broader biotech cell‑therapy sector and peers developing CAR‑T therapies.
US biotech market may see modest movement; European CAR‑T developers could be affected.
Limited to biotech investors; no broad macro impact.
Counterpoint
If data shows limited durability, the hype around CAR‑T could wane, hurting Gilead and peers.
Key entities
- CompanyGilead Sciences
US‑listed biotech developing CAR‑T therapies.
- SubsidiaryKite Pharma
Gilead's cell‑therapy unit presenting the data.
